Recruiting
Phase 1

Ketamine

Sponsor:

Stanford University

Code:

NCT04861051

Conditions

Epilepsy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ketamine

Study Details

Brief summary:

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Conditions

Epilepsy

Study ID

NCT04861051

Start date

Jul 26, 2021

Status verified date

Apr, 2026

Completion date

Aug 1, 2028

Anticipated

Primary completion date

Aug 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient in Stanford Epilepsy Monitoring Unit
  • Age >18 years old.

Exclusion Criteria:

  • Lifetime psychotic or bipolar disorder
  • Inability to speak, read or understand English
  • Pregnant or nursing females
  • Prior adverse ketamine response

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

other: Ketamine

Study participants will receive 0.5mg/kg of ketamine - one single infusion

Interventions

Ketamine

Study participants will receive 0.5mg/kg of ketamine - one single infusion

Primary outcome measure

  • Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale) [ Time Frame: up to 1 week ]

Central Contacts and Locations

Central contacts

Arjay Cordero

650-580-9000arjayc@stanford.edu

Locations

Stanford University School of Medicine

Recruiting

Palo Alto, California, United States, 94305

More Information

Sponsor

Stanford University

Last update posted

Apr 22, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stanford University on 2026-04-22.